Antheia is a biosynthesis company focused on transforming pharmaceutical manufacturing through engineered microorganisms that produce complex active pharmaceutical ingredients (APIs). The firm employs its advanced biosynthesis platform to generate critical drug ingredients domestically, reducing reliance on fragile global supply chains. Under an ongoing collaboration with the U.S. government’s BioMaP-Consortium, Antheia will scale commercial production of two essential pharmaceutical compounds in the United States. The company positions its technology as a solution to longstanding vulnerabilities in healthcare supply chains and aims to build a more resilient, on-shore source of medicines for the American market. To date, Antheia has secured $21 million in federal project investment dedicated to this initiative, including a recent $9 million expansion award. These funds will be deployed to increase manufacturing capacity and accelerate the company’s path to large-scale commercialization. No additional operating metrics or revenue figures were disclosed in the article.

Total raised

$173M

Funding rounds

5

Latest round

Grant

Latest activity

Mar 2026